

**FOR IMMEDIATE RELEASE: 20/MAR/2020**

Next Science Group  
Level 19, Tower A, The Zenith  
821 Pacific Highway, Chatswood  
NSW 2067  
Australia

Next Science, LLC  
10550 Deerwood Park Blvd  
Suite 300  
Jacksonville, FL 32256  
USA

## **Testing of Next Science Products Against Coronavirus (COVID-19)**

**SYDNEY, Australia, 20 March 2020** – Next Science is committed to the improvement of human health. Our core purpose is to eradicate biofilm protected bacteria and therefore, prevent and treat infection.

Next Science has a number of products on the market, with others expected to be launched this calendar year following EPA and FDA clearance, that are effective in the removal of COVID-19 like viruses. The currently marketed Next Science products contain viricidal concentrations of Benzalkonium chloride that yields a greater than 3.7 log reduction in strains of coronavirus in as little as 10 minutes. The surface disinfectant, currently under EPA review, is formulated with concentrations of acetic acid, that have been shown to be viricidal at a greater than 3 log reduction in coronavirus in only 60 seconds.

Progress continues in gaining EPA and FDA clearance in the United States for two new products to further address infection. Commercial launch of these products in the US market is expected to be H2 2020:

<b>Bactisure™ Surgical Lavage</b>	Removes bacteria, viruses and fungus in the surgical field
<b>SurgX™ Surgical Wound Gel</b>	Prevents infections in surgical procedures by protecting against bacteria, viruses and fungus in the surgical field
<b>BlastX™ Chronic Wound Gel</b>	Removes bacteria and viruses in infected wounds
<b>Surface Disinfectant</b>	Removes biofilms, bacteria, fungus and viruses (including COVID-19 like viruses) from hard surfaces Launch following EPA approval
<b>XPerience™ Surgical Rinse</b>	Removes biofilms, bacteria, viruses and fungus from the surgical field Launch following FDA clearance.

With the global increased awareness of infection prevention and control, Next Science is continuing product development and testing of new products. The safety of our staff and stakeholders is a priority. An infection management policy has been put in place at the Jacksonville Research and Development Centre to ensure safety and business continuity.

###

# NEXT SCIENCE®

***FOR FURTHER INFORMATION:***

Judith Mitchell  
Managing Director, Next Science Limited  
Phone: +61 2 9375 7989  
Email: [investorinquiries@nextscience.com](mailto:investorinquiries@nextscience.com)

**About the Next Science Group**

Next Science is an Australian Biotech company with headquarters in Sydney and its R&D and Operations centre in Jacksonville, Florida. Next Science pioneers innovative, proprietary material science technologies, including Xbio™ Technology, to address the problem of bacterial biofilms and already has a number of products on sale in the US. With proven, experienced management and scientific leadership, Next Science and its partners deliver break-through solutions that see beyond the current limits imposed by powerful bacterial colonies. Learn more at [www.nextscience.com](http://www.nextscience.com)